Author Archives: Marisa Wexler MS

Treprostinil Earns FDA Orphan Drug Designation for Treating IPF

The U.S. Food and Drug Administration (FDA) has granted treprostinil orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to therapies with the potential to substantially improve treatment for rare diseases (conditions affecting fewer than 200,000 people in the U.S.). The designation…

Partnership to Advance in Testing OATD-01, Potential IPF Therapy

Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization of OncoArendi’s OATD-01, an investigational treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Lung diseases like IPF are characterized by increased activity of enzymes called…

PFF Sharing Patient Stories, Photos to Mark PF Awareness Month

In recognition of September being Pulmonary Fibrosis Awareness Month, the Pulmonary Fibrosis Foundation (PFF) is working to raise awareness about the realities of this disease and how it affects people’s lives. The PFF is also conducting a social media campaign, “30 Facts in 30 Days,” to educate the public…

IPF Mortality Rates Decreasing in US, New Study Concludes

In the U.S., idiopathic pulmonary fibrosis (IPF) mortality rates decreased from 2004 to 2017, a new study shows. The data suggests the decline might be partly explained by a decline in smoking, but further research is needed to better understand the factors contributing to this trend. The study, “Mortality Trends…